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Background
HAE is an inherited disease characterized by sudden,
recurrent episodes of edema involving the skin, gastroin-
testinal, respiratory tract and other organs. Pregnancy
can mitigate, aggravate or have no effect on HAE C1-
INH edematous attacks. Short term prophylaxis is
recommended before labor and delivery when HAE C1-
INH symptoms have recurred frequently during the
third trimester of pregnancy. The administration of
pdhC1-INH in HAE is recommended as the first line
therapy in pregnancy. It is effective and safe. However,
pdhC1-INH is not available in many countries, such as
in Brazil. In these cases fresh frozen plasma might serve
as an alternative for STP (evidence level III). We
describe our experience with pdh C1-INH in two preg-
nant patients with HAE followed up in a Reference Cen-
ter in Rio de Janeiro, who received the medicine by
means of Justice.
Methods
CASE 1- DFT, a 29-year-old pregnant woman, with
HAE Type I (C4 = 5,0 mg/dL e C1-INH = 9,0 mg/dL)
and recurrent edema of hands, feets, lips, larynge and
abdominal pain. She received 1000 units of pdh
C1-INH, intravenously (IV), on the day of delivery.
CASE 2 - RSS, a 30 year-old pregnant woman, with
HAE Type I (C4 = 5,0 mg/dL e C1-INH = 5,0 mg/dL)
and episodes of swelling in the hands, feet and abdom-
inal pain. She also received 1000 units of pdh C1-INH,
IV, on the day of delivery.
Results
Both of them had uncomplicated labor under pdh
C1-INH prophylaxis. Healthy infants were born.
Conclusions
Our patients could experience uncomplicated labors
while being administered prophylactic pdhC1-INH,
despite having some attacks of HAE during pregnancy.
Short-term prophylaxis is important in individuals with
known HAE who are undergoing procedures which can
potentially precipitate an attack, as labor. pdhC1-INH
concentrate should be always available to be used, if
necessary.
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